growth factor-binding protein-3 (IGFBP-3) were produced to study the various forms of IGFBP-3 and to develop a specific immunofluorometric assay. We tested seven antibodies that showed no cross-reactions with the other five human IGFBPs. By immunoblothng, the main bands in normal serum were seen at >90, 45, 41, 29, and 25 kDa. In pregnancy serum, the 29-kDa band was stronger, and the double band at 41-45 kDa was weaker or totally absent. We characterized two immunofluorometric assays. IGF-l had no effect on either assay. Added IGF-ll lowered the amount of recombinant IGFBP-3 measured by the 5C1 1/7F8 assay, but not by the 1B615C11 assay. In normal serum and follicular fluid, IGFBP-3 measurements were lower by the 5C1 117F8 assay, but in most pregnancy sera and amniotic fluids the assays gave similar results. The 5C1 117F8 assay also detected IGFBP-3 in seminal plasma, whereas the 1B6/5C1 1 assay did not. We conclude that the results of IGFBP-3 measurement depend on the antibodies used, and that different antibodies are suitable for the IGFBP-3 measurement in different body fluids. Seminal plasma samples (n = 3) came from healthy male partners of infertile women. Normal human serum samples (n = 46) were from apparently healthy laboratory personnel (ages 20-60 years), and 139 samples were from children with no growth disorders or other metabolic disorders.
who may show IGFBP-3 forms similar to those seen in pregnancy serum (10).
Different polyclonal RIAs for IGFBP-3 give different
results (5) (6) (7) . Because the availability of polyclonal antibodies is limited, it would be desirable to generate monoclonal antibodies suitable for wider distribution and to obtain more uniform results. We have generated and tested several monoclonal antibodies against recombinant IGFBP-3 expressed for Escherichia coli (11), seeking antibodies that react against different epitopes of the peptide for use in an immunofluorometric assay (IFMA) for measuring IGFBP-3 concentrations in serum samples and body fluids.
MaterIals and Methods

Specimens
Amniotic fluids (n 10) were obtained from the specimens examined for routine prenatal diagnosis of chromosome abnormalities at [15] [16] Seminal plasma samples (n = 3) came from healthy male partners of infertile women. Normal human serum samples (n = 46) were from apparently healthy laboratory personnel (ages 20-60 years), and 139 samples were from children with no growth disorders or other metabolic disorders.
Pregnancy sera came from the first (n = 39), second (n = 7), and third (n = 18) trimesters. .All the samples were stored at -20#{176}C until tested.
Antibodies
Monoclonal antibodies (mAbs) were generated against recombinant human IGFBP3E coli kindly provided from 
Testing of Monoclonal Antibodies
Twenty-seven clones were found after the fusion. Seven mAbs with the highest affinity were chosen for ascites production and further testing. counts/mm per milliliter. We also performed a proteolysis assay, which measures the ability of a chosen fluid to proteolytically cleave 1251-labeled IGFBP-3 as shown in SDS-PAGE, as described previously (17) . or pooled normal human serum, all of which gave parallel dose-response curves. Cross-reactions were tested by IFMA against recombinant IGF-I (500 LgfL), IGF-II (500 zgfL), and the other five human IGFBPs (1 mg/L each). The effect of the IGFs on the IFMA was examined by incubating recombinant IGFBP3dhbo (100 .&gfL) with different concentrations of IGFs (3.1, 6.2, 12.5, 25, 50, and 100 .tgfL) for 0.5 h at 37#{176}C, or overnight at 20#{176}C, and comparing the results with those for IGFBP3dhbo without the IGFs. For doseresponse curves, we also incubated normal serum with 0.5 molIL HC1, or with 1 mauL acetic acid to dissociate the ternary complex. Dissociated IGFs were separated on an octadecylsilyl-silica column, as in the IGF-I RIA (see below).
Immunofluorometric
IGF-I was measured in serum samples (n = 22)byusing RIA kits from Incstar (Stillwater, MN). The assay includes acid treatment and octadecylsilyl-silica extraction to dissociate IGF-I from its binding proteins. The assay detection limit was 2.0 nmol/L, and intraassay variation was 10% for an IGF-I concentration of 13 nmol/L. 
Results
Immunoblotting
In SDS-PAGE and immunoblot analysis of normal serum, most of the seven antibodies reacted with the same bands but with different intensities.
In nonpregnancy serum, bands were seen at >90, 45,41, 29, and 25 kDa and a weaker band at 27 kDa (Fig. 1) . In latepregnancy serum, the 29-kDa band was stronger than in nonpregnancy serum (Fig. 1, a and c) ; faint bands were also visible at 34 and 17-22 kDa. In pregnancy serum, the bands at 45 and 41 kDa were weak or undetectable. In keeping with earlier studies, based on ligand blot analysis (8, 20), these bands in nonpregnancy serum bound IGF-I strongly, whereas in pregnancy serum they were undetectable (Fig. 2a) . mAb 7F8 differed from the other mAbs with respect to its reactivity against pregnancy serum. The 45-kI)a band was seen clearly by mAb 7F8. This mAb also recognized the 25-kDa band more strongly than the 29-kDa band (Fig. ib) . In immunoblotting, mAb 1B6 reacted very wealdy, making it necessary to add cobalt chloride (10 g/L) to the staining substrate to make the bands visible (Fig. la) . Amniotic fluid gave a band at 29 kDa; in ovarian follicular fluid, the bands were the same as seen in serum but were less intense (not shown). With mAb 5C11, the recombinant IGFBP3Go preparation showed not only the double 41-45-kDa band but also a 29-kDa band (Fig. ic) . The concentration used here was high, 0.3 pg/lane, and the recombinant IGFBP-3 had been thawed and frozen several times. Recombinant IGFBP3E coli migrated as a 33-kDa band (Fig. ic) . The bands at >90 and 47 kI)a, seen in most of the immunoblots, were also recognized by a totally different mAb, anti-PP14 (21), which was used as a control (Fig. 2b) .
In seminal plasma, the pattern was different: Only three mAbs gave any reaction at all. mAb 5C11 stained bands at 30 and 27 kDa strongly, with weak bands at 41 and <22 kI)a (Fig. ic, Fig. 2a) . mAb 7F8 identified the same bands, but more weakly, and mAb 4F3 gave a band at 22 kDa and less intense bands at 30 and <14
kDa (not shown). Ligand blot analysis
of seminal plasma demonstrated a strong band at 35 kfla (Fig. 2a ) and, after a longer exposure, less-intense bands at 25, 17, and 13 kDa. In dot-blot analysis, the seven m.Abs reacted strongly with recombinant IGFBP-3 but not with the other IGFBPs. We also tested mAbs 5C11 and 1B6 against rat IGFBPs 2-6; they reacted with rat IGFBP-3 only.
Immunofluorometric Assay
Seven niAbs were examined in 42 different combinations with various serum dilutions as samples (Fig. 3) IGF (tg/L) obtained by the combination of solid-phase 5C11/labeled 7F8 (5C11/7F8), which also had recognized IGFBP-3 in seminal plasma.
The detection limit of the 1B6/5C11 assay-i.e., the IGFBP-3 concentration giving the mean fluorescence signal of 20 replicates of a zero sample plus 2 SD-was 0.3 p.g/L. The measuring range of the 1B6/ 5C11 assay was 0.6-650 p.gfL (Fig. 4) . The detection limit of the 5C11/7F8 assay was 6 pg/L. The intraassay variations were 3.6-6.2% and interassay variations 4.9-11% (Table 1) . Analytical recoveries of added IGFBP-3CHO were 91-112% (Table 2) .
We made the following observations: 
42%. This phenomenon
was not seen for IGFBP-3 in nonpregnancy or in pregnancy serum with added IGFo II. IGF-II had no effect on the 1B6/5C11 assay. When tested alone, neither IGF-I nor IGF-II (500 g/L) gave cross-reactions in either assay.
Cross-reactions
with the other IGFBPs (1 mg/L) were minuscule (<0.06%).
5. By the 1B6/5C11 assay, the mean ± SD serum concentration of IGFBP-3 in adults (20-60 years, n = 46) was 4.6 ± 0.9 mgfL; by the 5C11/7F8 assay, it was 4.2 ± 0.8 mg/L (n = 31). Serum IGFBP-3 concentrations were found to increase with age until puberty and to (Fig. 6) . The IGFBP-3 concentrations measured in serum by the 1B6/5C11 assay correlated with the IGF-I concentrations (r = 0.78, P < 0.001, n = 23).
4-5
IGFBP-3 concentrations of some samples were measured by the 1B6/5C11 and 5C11/7F8 assays and compared. Normal serum and fofficular fluid gave lower IGFBP-3 concentrations in the 5C11/7F8 assay (Table  3) . Pregnancy sera that showed proteolytic activity had higher IGFBP-3 values than normal serum samples did in either assay. Some pregnancy sera gave very low results by the 1B6/5C11 assay, but were high by the 5C11/7F8 assay. When pregnancy sera from individual women at weeks 5-37 of gestation were tested, three of nine had a much lower IGFBP-3 concentration in the 1B6/5C11 assay than in the 5C11/7F8 assay. The reasons for this are not clear. In the protease assay all the samples degraded 1251-labeled IGFBP-3; in the ligand blotting assays, they did not bind '251-labeled IGF-I at all. The only suitable combination for seminal plasma was 5C11/7F8 (Table 3) .
Discussion
Several mAbs against IGFBP-3 were generated and examined by immunoblot analysis. In all, we tested 42 combinations of mAbs for use in an IGFBP-3 IFMA. Remarkably, one mAb was better for use in the solid phase than as the soluble label. Thus, whereas the combination of solid-phase 5C1 1/labeled 4F3 worked well, solid-phase 4F3/labeled 5C11 did not work at all. The same difference was seen in some other antibody pairs; perhaps there is steric hindrance at the immunoreactive site. From eight promising combinations we chose two different mAb pairs for IFMAs. The 1B6/5C11 assay detected IGFBP-3 better in normal serum than did the 5C11/7F8 assay, whereas the latter detected IGFBP-3 better in pregnancy serum, amniotic fluid, and seminal plasma. The proteolysis assay showed that pregnancy serum, amniotic fluid, and seminal plasma have the capacity to degrade labeled IGFBP-3. Probably the epitope for mAb 7F8 is near the IGF-II-bincling domain, because added recombinant IGF-II lowered the concentration of IGFBP-3#{176} as measured by the 5C11/7F8 assay. Apparently, pregnancy serum and amniotic fluid contain factors, possibly proteases, that remove IGF-II from IGFBP-3 and so allow labeled m.Ab 7F8 to react better with the antigen.
All of the RIAs with polyclonal antibodies (5-7) give
